Related Experiment Video

Updated: Sep 20, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases

Fuxun Yang1, Xiaoxiu Luo1, Jiajia Li1

  • 1Department of ICU, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|June 12, 2022
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show potential in treating organ fibrosis. Research indicates GLP-1RAs inhibit fibrosis in the heart, lung, liver, and kidney, offering new therapeutic avenues.

Area of Science:

  • Pharmacology and Therapeutics
  • Cell Biology
  • Organ Pathophysiology

Background:

  • Organ fibrosis, characterized by structural destruction and dysfunction, affects multiple organs and is a significant health concern.
  • Glucagon-like peptide-1 (GLP-1) is a hormone with a receptor (GLP-1R) found in various organs.
  • Synthetic GLP-1 receptor agonists (GLP-1RAs) are established treatments for diabetes mellitus.

Purpose of the Study:

  • To review the current research on the role of GLP-1 receptor agonists (GLP-1RAs) in mitigating organ fibrosis.
  • To explore the potential of GLP-1RAs as a therapeutic strategy for fibrotic diseases across different organs.

Main Methods:

  • Review of existing scientific literature on GLP-1RAs and their effects on fibrotic processes.
  • Analysis of studies investigating GLP-1RA action in the context of heart, lung, liver, and kidney fibrosis.

Main Results:

  • GLP-1RAs demonstrate anti-inflammatory, antioxidant, and cardiovascular protective properties.
  • Evidence suggests GLP-1RAs inhibit fibrosis in solid organs including the lung, heart, liver, and kidney.
  • GLP-1RAs offer promising therapeutic potential beyond diabetes management.

Conclusions:

  • GLP-1 receptor agonists show significant promise in combating organ fibrosis.
  • Further research into GLP-1RAs may yield novel treatments for diverse fibrotic conditions.
  • Understanding the anti-fibrotic mechanisms of GLP-1RAs can guide future therapeutic development.
Keywords:
Anti-inflammatoryAntioxidantDiabetes mellitusGLP-1Organ fibrosisOrgan injury

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

939
A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.8K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
443
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
278
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
313
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.9K